Edition:
India

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

34.95USD
17 Nov 2017
Change (% chg)

$-0.33 (-0.94%)
Prev Close
$35.28
Open
$35.25
Day's High
$35.43
Day's Low
$34.43
Volume
145,989
Avg. Vol
132,523
52-wk High
$37.49
52-wk Low
$15.97

Select another date:

Mon, Nov 6 2017

BRIEF-Aimmune Therapeutics says ‍CEO Stephen Dilly plans to retire by end of 2018​

* Aimmune Therapeutics Inc announces third quarter 2017 financial results and planned retirement of CEO by the end of 2018

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Oct 16 Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

BRIEF-Aimmune Therapeutics collaborates to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

* Aimmune Therapeutics announces clinical collaboration to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

BRIEF-Aimmune Therapeutics qtrly net loss per common share, basic and diluted $0.65

* Aimmune Therapeutics announces second quarter 2017 financial results

BRIEF-Aimmune enrolls first patient in Artemis European Phase 3 clinical trial

* Aimmune Therapeutics enrolls first patient in Artemis (ARC010) European Phase 3 clinical trial of AR101 for the treatment of peanut allergy Source text for Eikon: Further company coverage:

BRIEF-Aimmune Therapeutics reports on up-dosing in its ongoing phase 3 palisade trial of ar101 for peanut allergy

* Aimmune Therapeutics reports on up-dosing in its ongoing phase 3 palisade trial of ar101 for peanut allergy

Select another date: